Oncology Expansion

About New Day Diagnostics

New Day Diagnostics is an emerging, vertically integrated diagnostics company with a dual-pronged business model. It commercially offers ColoHealth, a blood-based test for colorectal cancer (CRC) screening with a validated 99.7% Negative Predictive Value (NPV), and provides diagnostic Contract Research Organization (CRO) services to other developers. The company is pursuing aggressive growth through strategic mergers, like EDP Biotech, and partnerships to expand its commercial footprint and pipeline into other cancers and infectious diseases. Its operations are supported by a CLIA-certified, ISO 13485-accredited laboratory, underpinning both its product commercialization and service offerings.

About Phargentis

Phargentis is a Swiss virtual biopharma company, founded in 2015, specializing in complex generics and SuperGenerics with a current focus on respiratory diseases. Operating as part of the Chemholding SA group, it leverages a capital-efficient, virtual model by outsourcing development and partnering for commercialization. Its strategy is built on securing API supply from its sister company, Cerbios-Pharma, and licensing out mature products to global pharma partners for distribution.

Therapeutic Areas